Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pharma AidsDHA:PHARMAID 73 EV-to-EBITDA is 15.60 as of Sep. 06, 2026, which is 31% below its 10-year median of 22.50. GuruFocus rates DHA:PHARMAID with a GF Score™ of 73/100 and a GF Value™ of BDT769.84 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 516 Medical Devices & Instruments companies, Pharma Aids ranks worse than 54.46% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Pharma Aids's enterprise value is BDT1,775.2 Mil.
Pharma Aids's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was BDT113.8 Mil. Therefore, Pharma Aids's EV-to-EBITDA for today is 15.60.
The historical rank and industry rank for Pharma Aids's EV-to-EBITDA or its related term are showing as below:
DHA:PHARMAID'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 14.32 Med: 22.5 Max: 301.44
Current: 15.6
During the past 13 years, the highest EV-to-EBITDA of Pharma Aids was 301.44. The lowest was 14.32. And the median was 22.50.
DHA:PHARMAID's EV-to-EBITDA is ranked worse than 54.46% of 516
companies
in the Medical Devices & Instruments industry
Industry Median: 14.3
vs DHA:PHARMAID: 15.60
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Pharma Aids (DHA:PHARMAID) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Pharma Aids's PE Ratio (TTM) for today is calculated as:
Pharma Aids's share price for today is BDT576.00.
Pharma Aids's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT24.880.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Pharma Aids's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DHA:PHARMAID vs ISRG, BDX, RMD: EV-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, Pharma Aids's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharma Aids EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Pharma Aids's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Pharma Aids's EV-to-EBITDA falls into.
Pharma Aids's current Enterprise Value is BDT1,775.2 Mil.
Pharma Aids's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT113.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharma Aids (DHA:PHARMAID) has a EV-to-EBITDA of 15.60 as of Sep. 06, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Pharma Aids. This is 31% below median its historical median of 22.50. Over the past decade, Pharma Aids' EV-to-EBITDA has ranged from 14.32 to 301.44. According to the industry distribution chart, Pharma Aids ranks #281 out of 516 companies in the Medical Devices & Instruments industry, placing it in the top 54.5%.
Is Pharma Aids' EV-to-EBITDA too high?
Pharma Aids' current EV-to-EBITDA of 15.60 is 31% below median its 10-year median of 22.50. Over the past 10 years, this metric has ranged from a low of 14.32 to a high of 301.44. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.30. Pharma Aids' value of 15.60 is 9.1% above this industry median. Based on the distribution chart, Pharma Aids ranks #281 out of 516 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Pharma Aids has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pharma Aids' EV-to-EBITDA compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Pharma Aids ranks #281 out of 516 companies for EV-to-EBITDA. This places Pharma Aids in the lower half of its industry. The industry median EV-to-EBITDA is 14.30. Pharma Aids' value of 15.60 is 9.1% above this benchmark. Historically, Pharma Aids' own EV-to-EBITDA has ranged from 14.32 to 301.44 over the past decade. While the company's 10-year median is 22.50 vs. the industry median of 14.30, Pharma Aids has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.30, based on 516 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pharma Aids's current EV-to-EBITDA of 15.60 is 9.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Pharma Aids. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharma Aids's current EV-to-EBITDA is 15.60, which is 31% below median its own 10-year median of 22.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharma Aids stock overvalued right now?
Based on GuruFocus' analysis, Pharma Aids (DHA:PHARMAID) is currently considered Modestly Undervalued. The stock's GF Value™ is BDT769.84, compared to a current price of BDT576.00 — trading 25.2% below its estimated fair value. The current EV-to-EBITDA is 15.60, which is 31% below median its 10-year median of 22.50 and 9.1% above the Medical Devices & Instruments industry median of 14.30. Pharma Aids' overall GF Score™ is 73/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Pharma Aids (DHA:PHARMAID), the current EV-to-EBITDA is 15.60 as of Sep. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharma Aids (DHA:PHARMAID) Overvalued in 2026?
Based on GuruFocus' analysis, Pharma Aids stock appears to be undervalued.
The current stock price of BDT576.00 is trading 25.2% below its estimated GF Value™ of BDT769.84.
GuruFocus considers Pharma Aids to be Modestly Undervalued.
Key valuation signals for DHA:PHARMAID:
EV-to-EBITDA: 15.60 (31% below median its 10-year median of 22.50)
GF Value™: BDT769.84 vs. price of BDT576.00 (25.2% below fair value)
Industry Position: 9.1% above the Medical Devices & Instruments median (#281 of 516)
No single metric tells the full story. See the DHA:PHARMAID stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharma Aids Ltd is a Bangladesh-based company engaged in the manufacturing of neutral glass ampoules, USP Type-I. Ampoules are used by pharmaceutical companies for filling liquid injections. The company produces different sizes of ampoules from 1ml to 25ml, in Clear and Amber color, and in Amber color, and of both Open Mouth (Form B and C) and Close Mouth (Form D, Din and Marzocchi type).
73GF Score
Get the complete analysis for DHA:PHARMAID
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:PHARMAID has been successfully added to your 
